Availability and accessibility of monoclonal antibodies in Bosnia and Herzegovina: Findings and implications.

ABSTRACT:

Background

Monoclonal antibodies (mAbs) represent the most numerous and significant group of biotherapeutics. While mAbs have undoubtedly improved treatment for many chronic diseases, including inflammatory diseases, they are typically expensive for health care systems and patients. Consequently, access to mAbs has been a problem for many patients especially among Central and Eastern European (CEE) countries. However, biosimilars can potentially help with costs, although there are concerns with their effectiveness and safety. This includes biosimilars for long-acting insulin analogues.

Aim

Assess the availability and use of biological medicines, including biosimilars within Bosnia and Herzegovina (B&H).

Methods

Assess the availability of mAbs via the current lists of

SUBMITTER: Tubic B 

PROVIDER: S-EPMC9413607 | biostudies-literature | 2021 Jan-Dec

REPOSITORIES: biostudies-literature